Diagnosing and treating ehrlichiosis and anaplasmosis in dogs (Proceedings)

Article

Tick-borne diseases of dogs and cats causing vasculitis leading to multisystemic dysfunction often characterized by thrombocytopenia and hyperglobulinemia.

     • Tick-borne diseases of dogs and cats causing vasculitis leading to multisystemic dysfunction often characterized by thrombocytopenia and hyperglobulinemia.

     • Recently reclassified – moved from the family Rickettsiaceae to the Anaplasmataceae.

Overview of etiologic agents

     • 3 pathogenic genera: Ehrlichia, Anaplasma, and Neorickettsia; we are concerned here with the first 2.

     • Ehrlichia spp. – divided into 3 groups:-

     • E. canis – intracyctoplasmic morulae found in circulating leukocytes.

     • E. chaffeensis – like E. canis, found in mononuclear cells; mainly a human pathogen but can causes disease in dog.

     • E. ewingii – canine granulocytic ehrlichiosis; like A. phagocytophila, infects granulocytic cells in dogs, but differs in geographic distribution (mainly found in southeastern and south-central USA).

     • Anaplasma spp. – 2 organisms of importance:-

           o phagocytophila – previously E. equi, E. phagocytophila, and HGE; infects mainly horses; infects granulocytic cells of dogs; serologic cross reactivity occurs with other Anaplasma spp. but uncommon with Ehrlichia spp.; same distribution as Lyme dz (same tick vector) - northeastern and upper Midwestern states, and California. No serologic cross reactivity with Borrelia, Bartonella or Rickettsia rickettsii.

           o platys – previously E. platys; tropism for platelets; does not share serologic cross reactivity with E. canis.

In this presentation, we will focus on E. canis and A. phagocytophilum.

Pathogenesis

Ehrlichia canis – Canine monocytotrophic ehrlichiosis.

     • Rhipicephalus sanguineus (brown dog tick) and occasionally Dermacentor variabilis transmits disease to dogs in saliva.

     • Incubation period – 1 to 3 weeks.

     • Severity and outcome of disease depends on infecting strain and dose of inoculum; German shepherd dogs seem more clinically affected

     • After infection – organisms multiply in macrophages then spread throughout hose:-

     • 3 stages of disease:-

           o Acute – spreads from bite site to the spleen, liver, and lymph nodes (causes organomegaly); then subclinical with mild thrombocytopenia; mainly endothelial cells affected; vasculitis; anti-platelet antibodies exacerbates thrombocytopenia; variable leukopenia; mild anemia; severity depends on organism.

           o Subclinical – organism persists; antibody response increases (hyperglobulinemia); thrombocytopenia persists.

           o Chronic – impaired bone marrow production (platelets, erythroid suppression); marrow hypercellular with plasma cells.

           o Multisystemic disease – including bleeding tendencies (thrombocytopenia and vasculitis), lymphadenopathy, splenomegaly, CNS, ocular (anterior uveitis), and lung.

Anaplasma phagocytophilumCanine granulocytic anaplasmosis.

     • Ixodes spp (I. scapularis in northeast, I. pacificus in California). transmit Dz in saliva

     • Incubation period – 1to 2 weeks (much shorter than for Lyme disease).

     • Reservoir hosts - white-footed mouse, chipmunks, wood rats, voles, and white-tailed deer; various bird species are also implicated in spread of disease.

     • After infection, organism binds and enters mainly neutrophils – multiply (morula) – rupture cell to release more organisms which infect more cells.

     • How organisms cause disease is not known; after ~ 10 days of infection, cellular and humoral immune mechanisms control infection.

     • Clinical findings are virtually always associated with acute disease period during the bacteremic phase – chronic disease has not been reported.

     • Mild illness typified by fever, lethargy and thrombocytopenia; polyarthritis occurs but rare in comparison to infection with E. ewingii; most dogs present in the spring, early summer and again in the fall.

Clinical signs

Ehrlichia canis

     • Duration of clinical signs from initial acute illness to presentation – usually > 2 months.

Acute

     • Bleeding diatheses – resulting in the development of petechia on mucous membranes (conjunctiva, skin), epistaxis, retinal hemorrhage due to thrombocytopenia and vasculitis

     • Fever – with depression, anorexia, weight loss.

     • Generalized lymphadenopathy/splenomegaly (in about 25% of cases).

     • Ticks – found in 40% of cases.

     • Respiratory – dyspnea (even cyanosis) and increased bronchovesicular sounds.

     • Diffuse CNS disease – meningitis (seizures, stupor, ataxia, vestibular dysfunction, cerebellar dysfunction, anisocoria).

     • Generalized or local hyperesthesia.

     • Polyarthritis can occur but is rare in E. canis infections – much more common in E. ewingii and A. phagocytophilum.

     • Most dogs recover without treatment – then enter a subclinical state.

Chronic

     • Spontaneous bleeding, anemia, and generalized lymphadenopathy.

     • Scrotal and limb edema.

     • Splenomegaly, hepatomegaly.

     • Uveitis, hyphema, retinal hemorrhages and detachment with blindness, corneal edema.

     • Seizures – rare.

Anaplasma phagocytophilum

     • Middle aged to older dogs are more likely diagnosed with the disease.

     • Most dogs present in the spring, early summer and again in the fall.

     • Mild illness typified by fever, lethargy, depression, anorexia.

     • Generalized musculoskeletal pain (reluctance to move, stiff, lameness) – 50% of dogs.

     • Actual joint pain is found in fewer than 10% of cases.

     • Very rarely – lymphadenopathy, splenomegaly, hepatomegaly, or CNS signs.

     • Although thrombocytopenia occurs, bleeding diatheses do not (clinically inapparent).

     • Dogs are susceptible to reinfection (with 5 mths or more between infections).

     • Serum antibody levels revert to negative levels by 7 to 8 mths post-treatment.

     • Chronic carrier state may exist although asymptomatic – none to date show chronic Dz.

     • Unknown if treatment removes carrier status.

     • Dogs co-infected with A. phagocytophilum and Borrelia (Lyme disease) will have more severe disease.

Diagnosis

Ehrlichia canis

Acute

     • CBC – thrombocytopenia (before onset of clinical signs), anemia, leukopenia (due to lymphopenia and eosinopenia), leukocytosis and monocytosis (as disease becomes more chronic); morulae (intracytoplasmic inclusions in leukocytes) are rare.

     • Mild increases in ALT, ALP, BUN, creatinine, and total bilirubin (rare).

     • Hyperglobulinemia – progressively increases 1–3 weeks post-infection.

     • Hypoalbuminemia – usually from renal loss.

     • Proteinuria – with or without azotemia.

Chronic

     • CBC – Pancytopenia typical; monocytosis and lymphocytosis may be present.

     • Hyperglobulinemia – size of globulin increase correlates with duration of infection; usually polyclonal gammopathy, but monoclonal (IgG) gammopathies occur.

     • Hypoalbuminemia.

     • Elevated BUN and creatinine – glomerulonephritis and renal interstitial plasmacytosis.

Serology

     • Indirect FA – positive by 7 days post-infection (some not until 4 wks PI); most clinically useful and reliable method; highly sensitive – poor specificity with cross-reactivity with E. chaffeensis and E. ewingii (not problems in the northeast) but not A. phagocytophilum (in A. phagocytophilum IFA, slight cross-reactivity with E. canis serum).

     • Titers usually 1:80 are diagnostic; paired titers recommended as single titer can reflect past infection; titer progressively declines over 6 to 9 months after treatment. high seroprevalence compared to disease prevalence.

     • Canine Snap® 3 and 4Dx? Diagnostic Test (IDEXX Laboratories, Westbrook, ME) – an in-house snap test which tests for antibodies against Lyme disease and E. canis, and heartworm antigen (4D included A. phagocytophilum); detects positive titers to E. canis at an equivalent IFA titer of > 1:500; sensitivity of 95%; specificity of 100% (according to manufacturer); also detects antibodies against E. chaffeensis but not E. ewingii; as with any serologic test, predictive value also depends not only on sensitivity and specificity but also prevalence; in low prevalence areas, likely to get a high false positive rate; could get false positives by reactions to non-pathogenics; confirm +ve test with IFA.

     • Western Blotting – may be used to differentiate mixed infection.

     • PCR – proving to be very sensitive in early detection of experimental infections (positive as early as 4 to 10 days PI) but sensitivity (using whole blood samples) in naturally infected cases not as clear cut; poor correlation with IFA in some studies; should be used in conjunction with serology to detect early cases; analysis of samples other than blood (joint fluid, CSF, aqueous humor, splenic aspirates) may be more clinically applicable.

Anaplasma phagocytophilum

     • Most reported cases have been found by finding morulae in neutrophils on the CBC; however, more and more cases are being diagnosed in asymptomatic dogs using the Snap® 4Dx? Diagnostic Test (IDEXX Laboratories, Westbrook, ME).

     • Up to ~40% of neutrophils can contain morulae (are present for 5 to 9 days experimentally); about 80% have mild thrombocytopenia and lymphopenia, and most have eosinopenia (but not neutrophilia); some have mild anemia and hypoalbuminemia.

Serology

     • Sero-conversion (using indirect IFA) occurs about 2 to 5 days after appearance of morulae in blood, and titers remain detectable for about 8 months after acute infection.

     • Need paired samples 2 to 3 weeks apart to show 4 fold increase in titer because 40% of acutely ill morulae-positive dogs can be sero-negative at presentation; low titers may be because of a previous infection.

     • Serologic cross-reaction does occur with other Anaplasma spp. and E. canis (although mild) but becomes less cross-reactive during convalescences; no cross-reactions with Borrelia or Rickettesia. A positive Snap® 4Dx? Diagnostic Test in southeast US is most likely due to A. platys; in the northeast US, it is most likely A. phagocytophilum.

     • Also, by using the Snap® 4Dx? Diagnostic Test, if there is a positive E. canis and A. phagocytophilum reaction, the dog could have both infections, or Anaplasma with a cross reaction with E. canis (and likely an acute active infection and not convalescent), but unlikely to have E. canis alone because there is little cross-reactivity between E.canis antigen and A. phagocytophilum-positive serum.

     • PCR – more sensitive than finding morulae and provides a very species-specific test in the right hands – not well reported in diagnosing naturally-infected cases.

Treatment

     • Only E. canis cases might need hospitalization; stabilize medical for anemia and hemorrhagic tendency (due to thrombocytopenia) – fluids, blood transfusion, platelet-rich plasma (in emergency), or treat for the results of pancytopenia (sepsis) with broad spectrum antibiotics if necessary.

     • Short-term therapy of glucocorticoids (2 to 5 days of 2mg/kg/day of prednisone) may be beneficial early in acute disease when life-threatening thrombocytopenia is present, and may help other immune mediated associations of the disease (polyarthritis, vasculitis, meningitis).

     • Androgenic steroids (oxymetholone or nandrolone decanoate) or granulocyte colony-stimulating factor (Neupogen®, Amgen) – to stimulate bone marrow production in chronically E. canis-affected dogs with hypoplastic marrows may be indicated.

     • Doxycycline is the drug of choice for both E. canis and A. phagocytophilum (5 mg/kg, PO, q12h for 3 to 4 weeks) – see rapid (within 72 hrs of onset of treatment) improvement of platelet count in acute cases; recovered dogs still able to become re-infected.

     • Imidocarb dipropionate (Imazol®, Schering-Plough Animal Health – 5mg/kg, IM, once then repeat in 2 to 3 weeks); reasonable alternative to doxycycline; pretreatment with atropine may lessen anticholinergic adverse effects (salivation, serous nasal discharge, diarrhea).

     • Both doxycycline and imidocarb give ~ 95% cure rate – not improved if used together.

     • Other effective antibiotics include: minocycline, tetracycline, oxytetracycline, and chloramphenicol; enrofloxacin is not effective.

     • A seropositive (by the 4Dx test) asymptomatic dog for A. phagocytophilum - could treat with doxycycline with hope (unknown if it does) that it removes carrier state, but as carriers seem to remain subclinical, this practice is controversial.

     • Prognosis in acute E. canis and A. phagocytophilum infections is excellent; response may take months in chronic ehrlichiosis.

     • Control tick infestations with dips or sprays containing dichlorvos, chlorfenvinphos, dioxathion, propoxur, or carbaryl; flea and tick collars may reduce reinfestation but reliability unproven; selamectin topically (Revolution®, Pfizer) monthly; a combination of imidacloprid and permethrin is effective; avoid tick-infested areas.

     • Examine dogs for concurrent infections that exist in the region frequented by the pet.

     • Zoonotic potential – serologic evidence indicates that E. canis (or possibly a related species) occurs in people; probably not directly infected from dogs; tick exposure thought to be necessary; R. sanguineus probably not the vector in humans.

References

Eddleston SM, Diniz PP, Neer TM et al: Doxycycline clearance of experimentally induced chronic Ehrlichia canis infection in dogs. J Vet Int Med 21:1237-42, 2007.

Neer TM and Harrus S. Canine monocytotrophic Ehrlichiosis and Neorickettsiosis. In:Greene GE (ed) Infectious diseases of the dog and cat. 3rd ed. Philadelphia, Saunders. 203-216, 2006.

Greig B and Armstrong PJ. Canine granulocytotrophic anaplasmosis. In:Greene GE (ed) Infectious diseases of the dog and cat. 3rd ed. Philadelphia, Saunders. 21-224, 2006.

Recent Videos
Richard Gerhold, DVM, MS, PhD, DACVM (Parasitology)
merck leptospirosis panel
merck leptospirosis panel
merck leptospirosis panel
dvm360 Live! with Dr. Adam Christman
Vet Perspective parasitology discussion
Vet Perspective parasitology discussion
© 2024 MJH Life Sciences

All rights reserved.